PMID- 28440045
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20220214
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Print)
IS  - 1930-7381 (Linking)
VI  - 25
IP  - 5
DP  - 2017 May
TI  - Coadministration of lorcaserin and phentermine for weight management: A 12-week, 
      randomized, pilot safety study.
PG  - 857-865
LID - 10.1002/oby.21811 [doi]
AB  - OBJECTIVE: To assess the short-term tolerability of lorcaserin alone or with two 
      dose regimens of phentermine. METHODS: This was a 12-week, randomized, 
      double-blind, pilot safety study of N = 238 nondiabetic patients with obesity or 
      overweight with >/=1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; 
      LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 
      mg twice daily (LOR BID+PHEN BID). Patients reporting >/= 1 of 9 potentially 
      serotonergic adverse events (AEs), mean weight loss (WL), and >/=5% WL are 
      reported. RESULTS: N = 238 were randomized, and N = 235 were treated. N = 94 
      reported potentially serotonergic AEs: 37.2% LOR BID, 42.3% LOR BID+PHEN QD, and 
      40.5% LOR BID+PHEN BID. AEs leading to discontinuation were reported 
      approximately twice as often in the LOR BID+PHEN BID group versus the LOR BID 
      group. Mean WL was 3.5 kg/3.3%, 7.0 kg/6.7%, and 7.6 kg/7.2% for LOR BID, LOR 
      BID+PHEN QD, and LOR BID+PHEN BID, respectively. At least 5% WL was achieved by 
      28.2% LOR BID, 59.0% LOR BID+PHEN QD (P = 0.0002 vs. LOR BID), and 70.9% LOR 
      BID+PHEN BID (P < 0.0001 vs. LOR BID) patients. CONCLUSIONS: Phentermine added to 
      lorcaserin enhanced short-term weight loss but did not increase incidence of 
      potentially serotonergic AEs; however, phentermine twice daily increased 
      discontinuation compared to both lorcaserin alone and lorcaserin plus phentermine 
      once daily.
CI  - (c) 2017 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The 
      Obesity Society (TOS).
FAU - Smith, Steven R
AU  - Smith SR
AD  - Center for the Metabolic Origins of Disease, Sanford Burnham Prebys Medical 
      Discovery Institute, Orlando, Florida, USA.
AD  - Translational Research Institute for Metabolism and Diabetes, Florida Hospital, 
      Orlando, Florida, USA.
FAU - Garvey, W Timothy
AU  - Garvey WT
AD  - Department of Nutrition Sciences, University of Alabama at Birmingham, and the 
      Birmingham VA Medical Center, Birmingham, Alabama, USA.
FAU - Greenway, Frank L
AU  - Greenway FL
AD  - Pennington Biomedical Research Center, Louisiana State University System, Baton 
      Rouge, Louisiana, USA.
FAU - Zhou, Sharon
AU  - Zhou S
AD  - Eisai Medical and Scientific Affairs, Eisai Inc., Woodcliff Lake, New Jersey, 
      USA.
FAU - Fain, Randi
AU  - Fain R
AD  - Formerly Eisai Inc., Woodcliff Lake, New Jersey, USA.
FAU - Pilson, Robert
AU  - Pilson R
AD  - Formerly Eisai Inc., Woodcliff Lake, New Jersey, USA.
FAU - Fujioka, Ken
AU  - Fujioka K
AD  - Department of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California, 
      USA.
FAU - Aronne, Louis J
AU  - Aronne LJ
AD  - Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01987427
GR  - P30 DK079626/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Benzazepines)
RN  - 637E494O0Z (lorcaserin)
RN  - C045TQL4WP (Phentermine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Obesity Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Benzazepines/administration & dosage/pharmacology/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phentermine/administration & dosage/pharmacology/*therapeutic use
MH  - Pilot Projects
MH  - Weight Loss/*drug effects
MH  - Young Adult
PMC - PMC5518190
EDAT- 2017/04/26 06:00
MHDA- 2017/11/29 06:00
PMCR- 2017/07/20
CRDT- 2017/04/26 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2017/01/07 00:00 [revised]
PHST- 2017/01/30 00:00 [accepted]
PHST- 2017/04/26 06:00 [entrez]
PHST- 2017/04/26 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/07/20 00:00 [pmc-release]
AID - OBY21811 [pii]
AID - 10.1002/oby.21811 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2017 May;25(5):857-865. doi: 10.1002/oby.21811.